Journal of Clinical Epidemiology
Volume 54, Issue 1 , Pages 68-85 , January 2001

Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation

  • Peter Gilbert

      Affiliations

    • Department of Biostatistics, Harvard School of Public Health, 655 Huntington Ave., Boston, MA 02115, USA
    • Corresponding Author InformationCorresponding author. Tel.: (617) 432-2899; fax: (617) 739-7181. E-mail address:
    • ,
  • Steve Self

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    • ,
  • Malla Rao

      Affiliations

    • National Institute of Child Health and Human Development, Bethesda, MD, USA
    • ,
  • Abdollah Naficy

      Affiliations

    • National Institute of Child Health and Human Development, Bethesda, MD, USA
    • ,
  • John Clemens

      Affiliations

    • National Institute of Child Health and Human Development, Bethesda, MD, USA

Received 3 February 1999 ,Revised 29 March 2000 ,Accepted 10 April 2000.

References 

  1. Berman PW, Gray A, Wrin T, Vennari JC, Eastman DJ, Nakamura GR, et al. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. J Infect Dis. 1997;176:384–397
  2. Gilbert PB, Self S, Ashby M. Statistical methods for assessing differential vaccine protection against HIV types. Biometrics. 1998;54:799–814
  3. Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B) (a final report). Hepatology. 1981;1:377–385
  4. Francis DP, Hadler SC, Thompson SE, Maynard JE, Ostrow DG, Altman N, et al. The prevention of hepatitis B with vaccine. Ann Int Med. 1982;97:362–366
  5. Clemens JD, Sack DA, Harris JR, et al.  Field trial of oral cholera vaccines in Bangladesh (results from three-year follow-up). Lancet. 1990;335:270–273
  6. van Loon F. Cholera (developments in prevention and cure). Trop and Geograph Med. 1993;45:269–273
  7. Lanata CF, Black RE, del Aguila R, Gil A, Verastegui H, Gerna G, et al. Protection of Peruvian children against rotavirus diarrhea of specific serotypes of one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. J Infect Dis. 1989;159:452–459
  8. Ukae S, Nakata S, Noriaki A, Kogawa K, Chiba S. Efficacy of rhesus rotavirus vaccine MMU-18006 against gastroenteritis due to serotype 1 rotavirus. Vaccine. 1994;12:933–939
  9. Jin Q, Ward RL, Knowlton DR, Gabbay YB, Linhares AC, Rappaport R, et al. Divergence of VP7 genes of G1 rotaviruses isolated from infants vaccinated with reassortant rhesus rotaviruses. Arch Virol. 1996;141:2057–2076
  10. Rennels MB, Glass RI, Dennehy PH, Bernstein DI, Pichichero ME, Zito ET, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines—report of the national multicenter trial. Pediatrics. 1996;97:7–13
  11. Ammann AJ, Addiego J, Wara DW. Lubin B, Smith WB, Mentzer WC. Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy. N Engl J Med. 1977;297:897–900
  12. Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA. 1977;238:2613–2616
  13. John AB, Ramlal A, Jackson H, Maude GH, Sharma AW, Serjeant GR. Prevention of pneumococcal infection in children with homozygous sickle cell disease. Br Med J Clin Res Ed. 1984;288:1567–1570
  14. Pyrohonen S, Suni J, Romo M. Clinical trial of a subunit of influenza vaccine. Scand J Infect Dis. 1981;13:95–99
  15. Govaert TME, Thijs CTM, Masurel N, Sprenger MJW, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. JAMA. 1994;272:1661–1665
  16. Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med. 1988;319:608–614
  17. Alonso PL, Smith T, Armstrong Schellenberg JRM, Masanja H, Mwankusye S, Urassa H, et al. Randomized trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in southern Tanzania. Lancet. 1994;344:1175–1181
  18. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, et al. A new classification for HIV-1. Nature. 1998;391:240
  19. Jukes TH, Cantor CR. Evolution of protein molecules. In:  Munro HN editors. Mammalian Protein Metabolism. New York: Academic Press;; 1999;p. 22–132
  20. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol. 1980;16:111–120
  21. Li WH, Gu X. Estimating evolutionary distances between DNA sequences. Methods Enzymol. 1996;266:449–459
  22. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 1994;266:1024–1027
  23. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol. 1995;69:6609–6617
  24. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 protein of human immunodeficiency virus type 1. J Virol. 1996;70:1100–1108
  25. Moore J, Trkola A. HIV Type 1 coreceptors neutralization serotypes, and vaccine development. AIDS Res Hum Retroviruses. 1997;13:733–736
  26. Nyambi PN, Nkengasong J, Lewi P, Andries K, Janssens W, Fransen K, et al. Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J Virol. 1996;70:6235–6243
  27. Clements-Mann ML. Lessons for AIDS vaccine development from non-AIDS vaccines. AIDS Res Hum Retroviruses. 1998;14(Suppl. 3):S197–S203
  28. Gilbert PB, Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection. Stat Med (in press).
  29. Smith PG, Rodrigues LC, Fine PEM. Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. Int J Epidemiol. 1984;13:87–93
  30. Halloran ME, Haber MJ, Longini IM. Interpretation and estimation of vaccine efficacy under heterogeneity. Am J Epidemiol. 1992;136:328–343
  31. Gilbert PB. Interpretability and robustness of sieve analysis models for assessing HIV strain variations in vaccine efficacy. Stat Med (in press).
  32. Gilbert PB, Lele S, Vardi Y. Maximum likelihood estimation in semiparametric selection bias models with application to AIDS vaccine trials. Biometrika. 1999;86:27–43
  33. Armitage P, Berry G. Statistical Methods in Medical Research. 3rd Edition. Malden, MA: Blackwell Science, Inc; 1994;
  34. Breslow NE, Day NE. Statistical Methods in Cancer Research, Volume 1. Lyon: International Agency for Research on Cancer; 1980;
  35. Siegal S, Castellan NJ. Nonparametric Statistics for the Behavioral Sciences. 2nd Edition. New York: McGraw-Hill Book Company; 1988;
  36. Agresti A. Categorical Data Analysis. New York: John Wiley; 1990;
  37. Mehta C, Patel N. StatXact 4 Windows. Cambridge, MA: Cytel Software Corporation; 1998;
  38. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141–1154
  39. Anonymous . SAS/STAT User's Guide. Cary, NC: SAS Institute; 1990;
  40. Anderson JA. Separate sample logistic discrimination. Biometrika. 1972;59:19–35
  41. Cox DR. The Analysis of Binary Data. London: Methuen; 1970;pp. 103–8.
  42. van Loon F, Clemens JD, Knowlton DR, Chakraborty J, Rao MR, Kay BA, et al. Field trial of inactivated oral cholera vaccines in Bangladesh (results from 5 years of follow-up). Vaccine. 1996;14:162–166
  43. McCullagh P. Regression models for ordinal data (with discussion). J Royal Stat Soc B. 1980;42:109–142
  44. Agresti A. Analysis of Ordinal Categorical Data. New York: John Wiley; 1984;
  45. Connor RI, Korber BTM, Graham BS, Bahn BH, Ho DD, Walker BD, et al. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol. 1998;72:1552–1576
  46. Berman PW, Matthews TJ, Riddle L, Champe M, Hobbs MR, Nakamura GR, et al. Neutralization of multiple laboratory and clinical isolates of HIV-1 by antisera raised against gp120 from the MN isolate of HIV-1. J Virol. 1992;7:4464–4469
  47. Myers G, Korber B, Hahn BH, et al.  Human Retroviruses and AIDS (A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences). Retroviruses and AIDS Database. Los Alamos, NM: Los Alamos National Laboratories;; 1992;
  48. La Rosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, et al. Conserved sequences and structural elements in the HIV-1 principal neutralizing determinant. Science. 1990;249:932–935
  49. Clemens J, Sack D, Harris J, van Loon F, Chakraborty J, Ahmed F, et al. ABO blood groups and cholera (new observations on specificity of risk and modification of vaccine efficacy). J Infect Dis. 1989;159:770–773
  50. Bart K, Huq Z, Khan M, Mosley WH. Seroepidemiologic studies during a simultaneous epidemic of infection with El Tor Ogawa and classical Inaba Vibrio cholerae. J Infect Dis. 1970;121:S17–S24
  51. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics. 1995;51:524–532
  52. Cuzick J. The efficiency of the proportions test and the logrank test for censored survival data. Biometrics. 1982;38:1033–1039
  53. Gail MH. Applicability of sample size calculations based on a comparison of proportions for use with the logrank test. Cont Clin Trials. 1985;6:112–119
  54. Bruyn GRW, van Furth R. Pneumococcal polysaccharide vaccines (indications, efficacy and recommendations). Eur J Clin Microbiol Infect Dis. 1991;10:897–910
  55. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae.. J Clin Microbiol. 1995;33:2759–2762
  56. Bolan G, Broome CV, Facklam RR, Plikaytis BD, Fraser DW. Schlech III WF. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Int Med. 1987;104:1–6
  57. Broome CV, Facklam RR, Fraser DW. Pneumococcal disease after pneumococcal vaccination. N Engl J Med. 1980;303:549–552
  58. Ekwurzel GM, Simmons JS, Dublin LI, Felton LD. Studies on immunizing substances in pneumococci. VIII. Report on field tests to determine the prophylactic value of a pneumococcus antigen. Public Health Rep. 1938;53:1877–1893
  59. MacLeod CM, Hodges RG, Heidelberger M, Bernhard WG. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med. 1945;82:445–465
  60. Austrian R. Vaccine of pneumococcal capsular polysaccharides and the prevention of pneumococcal pneumonia. In:  Beers RF,  Bassett EG editor. The Role of Immunological Factors in Infectious, Allergic, and Autoimmune Processes. New York: Raven Press; 1976;p. 79–89
  61. Wong W-Y, Overturf GD, Powars DR. Infection caused by Streptococcus pneumoniae in children with sickle cell disease (epidemiology, immunologic mechanisms, prophylaxis, and vaccination). Clin Infect Dis. 1992;14:1124–1136
  62. Rida W, Fast P, Hoff R, Fleming T. Intermediate-size trials for the evaluation of HIV vaccine candidates (a workshop summary). J Acq Immune Defic Syndr Hum Retrovirology. 1997;16:195–203
  63. Halloran ME, Longini IM, Haber MJ, Struchiner CJ, Brunet RC. Exposure efficacy and change in contact rates in evaluating prophylactic HIV vaccines in the field. Stat Med. 1994;13:357–377
  64. Sugaya N, Nerome K, Ishida M, Matsumoto M, Mitamura K, Nirasawa M. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B. JAMA. 1994;272:1122–1126
  65. Gilbert PB, Bosch RJ. Applications of semiparametric biased sampling models to AIDS vaccine and treatment trials. In: Probability Theory and Mathematical Statistics, Proceedings of the 7th Vilnius Conference on Probability Theory and Mathematical Statistics. Utrecht, the Netherlands: VSP/Vilnius, Lithuania: TEV1998.

PII: S0895-4356(00)00258-4

Journal of Clinical Epidemiology
Volume 54, Issue 1 , Pages 68-85 , January 2001

Article Tools

* Image Usage & Resolution